Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma

Abstract

IntroductionPancreatic cancer is a truculent disease with limited treatment options and a grim prognosis. Immunotherapy has shown promise in treating various types of cancer, but its effectiveness in pancreatic cancer has been lacking. As a result, it is crucial to identify markers associated with immunological pathways in order to improve the treatment outcomes for this deadly cancer. The purpose of this study was to investigate the diagnostic and prognostic significance of three markers, CD8, CD68, and VISTA, in pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer.MethodsWe analyzed gene expression data from Gene Expression Omnibus (GEO) database using bioinformatics tools. We also utilized the STRING online tool and Funrich software to study the protein-protein interactions and transcription factors associated with CD8, CD68, and VISTA. In addition, tissue microarray (TMA) and immunohistochemistry (IHC) staining were performed on 228 samples of PDAC tissue and 10 samples of normal pancreatic tissue to assess the expression levels of the markers. We then correlated these expression levels with the clinicopathological characteristics of the patients and evaluated their survival rates.ResultsThe analysis of the GEO data revealed slightly elevated levels of VISTA in PDAC samples compared to normal tissues. However, there was a significant increase in CD68 expression and a notable reduction in CD8A expression in pancreatic cancer. Further investigation identified potential protein-protein interactions and transcription factors associated with these markers. The IHC staining of PDAC tissue samples showed an increased expression of VISTA, CD68, and CD8A in pancreatic cancer tissues. Moreover, we found correlations between the expression levels of these markers and certain clinicopathological features of the patients. Additionally, the survival analysis revealed that high expression of CD8 was associated with better disease-specific survival and progression-free survival in PDAC patients.ConclusionThese findings highlight the potential of CD8, CD68, and VISTA as diagnostic and prognostic indicators in PDAC.

The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma

“…VISTA is an immunological checkpoint protein, and its overexpression, together with increased levels of the VSIG3 and PSGL-1 receptors in the tumor microenvironment, may be involved in the modulation of immune responses to cancer. There is growing evidence of the importance of the immunosuppressive role of VISTA in cancer progression [ 20 , 41 , 57 , 62 , 63 , 69 – 73 ]. The presence of VISTA on the surface of cancer cells can not only modulate immune cells but also potentially play a much broader role in cancer biology.…”

Comprehensive immune modulation mechanisms of Angong Niuhuang Wan in ischemic stroke: Insights from mass cytometry analysis

“…Our study highlighted a pronounced inflammatory response in the vehicle group, evidenced by elevated markers like CD4, CD8a, and CD44. CD8a is a potential prognostic and diagnostic marker for inflammatory disorders and tumors, 48 , 49 used to predict severity in chronic rhinosinusitis and as a biomarker for rheumatoid arthritis. 50 CD8a expression is downregulated in a model of bronchopulmonary dysplasia.…”

Current and future immunotherapeutic approaches in pancreatic cancer treatment

“…In contrast to checkpoints that mainly control T-cell effector function and exhaustion, VISTA has various roles. It aids in the functioning of MDSCs, governs the activation of NK cells, promotes the survival of Tregs, restricts antigen presentation on APCs, and also maintains T cells in a state of rest [ 354 – 356 ]. The expression of VISTA is associated with a more favorable prognosis in cases of pancreatic cancer [ 357 ].…”